Biotech Bay
Filter News
Found 85,050 articles
-
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
3/28/2024
Kodiak Sciences Inc., reported business highlights and financial results for the quarter and year ended December 31, 2023.
-
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
3/27/2024
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) status to pegozafermin in patients with MASH.
-
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
3/27/2024
Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT) today announced the completion of a Phase 1 hepatic impairment study with denifanstat, a selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
-
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
3/27/2024
Innovent Biologics, Inc. announces that the first participant has been successfully dosed with IBI310 in combination with sintilimab in a randomized, controlled, multicenter Phase 3 clinical trial, for resectable MSI-H/dMMR[1] colon cancer neoadjuvant therapy.
-
Synthego Announces CEO Transition to Focus on Enabling CRISPR Therapeutics
3/27/2024
Synthego Corporation, a leading provider of genome engineering solutions, announced that Paul Dabrowski will step down as Chief Executive Officer, effective immediately.
-
Xcell Biosciences Announces New Scientific and Business Advisory Board
3/27/2024
Xcell Biosciences Inc., an instrumentation company focused on cell and gene therapy applications, announced the formation of a new scientific and business advisory board composed of some of the leading minds in the industry.
-
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
3/27/2024
Jaguar Health, Inc. announced that the company will conduct an investor webcast on Monday, April 1, 2024 at 8:30 a.m. Eastern Standard Time to review fourth-quarter 2024 financials and provide corporate updates.
-
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 27, 2024
3/27/2024
Revance Therapeutics, Inc. announced new hire grants totaling an aggregate of 222,452 inducement restricted stock units to 29 employees.
-
Aqtual to Present Poster at American Association for Cancer Research Annual Meeting 2024
3/27/2024
Aqtual, Inc. announced that it will present a poster at the American Association for Cancer Research Annual Meeting, held April 5-10, 2024, in San Diego, California.
-
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
3/27/2024
DURECT Corporation announced financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.
-
American Shared Hospital Services Reports Fourth Quarter 2023 Financial Results
3/27/2024
American Shared Hospital Services announced financial results for the fourth quarter ended December 31, 2023.
-
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
3/27/2024
Vaxart, Inc. announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2024 in Washington, D.C. on Wednesday, April 3, 2024.
-
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
3/27/2024
Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced three oral presentations and one poster presentation at the 33rd Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2024, being held March 27-31, 2024 in Kyoto, Japan.
-
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
3/27/2024
ASLAN Pharmaceutical (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will give a virtual company presentation at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders, to be held virtually on Thursday, March 28, 2024.
-
GRAIL Presents New Data on Galleri® and Its Methylation Platform at the Annual American Association for Cancer Research (AACR) Meeting
3/27/2024
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, will present new data on the clinical utility of its Methylation Platform across the cancer continuum, and the impact of multi-cancer early detection (MCED) testing in guiding diagnostic evaluation at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, Calif., April 5-10, 2024.
-
Metagenomi Reports Business Updates and Full Year 2023 Financial Results
3/27/2024
Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today reported financial results for the full year ended December 31, 2023, and additional business updates.
-
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
3/27/2024
Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company will present four scientific posters at the upcoming 2024 American Thoracic Society (ATS) International Conference, taking place in San Diego, California from May 17-22, 2024.
-
NeuroPace to Present at the Needham 23rd Annual Healthcare Conference
3/27/2024
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will present at the Needham 23rd Annual Healthcare Conference, taking place virtually from April 8-11.
-
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
3/27/2024
BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2023 and filed its annual report on Form 10-K with the Securities and Exchange Commission.
-
Tenon(R) Medical Announces Positive Fusion Results in First Patients Reaching 12-Month Follow Up in an IRB Approved, Multi-Centered, Post-Market Study Utilizing the Catamaran(R) SI Joint Fusion System
3/26/2024
Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint disorders, today announced significant progress in the post-market study utilizing the Company's Catamaran® SI Joint Fusion System.